This week in psychedelic business news: more evidence supporting ketamine for depression; a new use for MDMA; Lobe Sciences makes a leap in treating PTSD; Delix raises big bucks; and BetterLife Pharma patents solution for cluster headaches.
Medavie Blue Cross partners with medical research company Braxia Scientific to cover ketamine care for veterans at Canadian Rapid Treatment Centres of Excellence.
End of content
End of content
By signing up to the Psychedelic Spotlight newsletter you agree to receive electronic communications from Psychedelic Spotlight that may sometimes include advertisements or sponsored content.